A review on modafinil: the characteristics, function, and use in critical care

Hashemian, Seyed Mohammadreza; Farhadi, Tayebeh

doi:10.1080/21556660.2020.1745209

Cited by 25 publications

(13 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The compound was developed a long ago as a potent, long-lasting wake-promoting substance and was approved in 1998 by FDA (Provigil®) for the treatment of sleep disorders [64]. Modafinil normalizes cognitive functions in sleep-deprived conditions, and being non-addictive has been clinically investigated for nicotine and cocaine addiction, moreover for attention deficit, affective disorders, depressions, and schizophrenia, while preclinical evidence suggests effects also in Alzheimer's and Parkinson's diseases [65][66][67][68]. A further assessment indicates that modafinil leads to a slight improvement of fatigue syndrome in chronic neurological disorders [69], myotonic dystrophy type 2 [70], and surprisingly also ALS [71], thus confirming and validating the prioritization of modafinil that emerged from our SAve-RUNNER/GSEA drug-disease network predictive results.…”

Section: Discussionmentioning

confidence: 99%

Drug Repurposing: A Network-based Approach to Amyotrophic Lateral Sclerosis

et al. 2021

View full text Add to dashboard Cite

The continuous adherence to the conventional "one target, one drug" paradigm has failed so far to provide effective therapeutic solutions for heterogeneous and multifactorial diseases as amyotrophic lateral sclerosis (ALS), a rare progressive and chronic, debilitating neurological disease for which no cure is available. The present study is aimed at finding innovative solutions and paradigms for therapy in ALS pathogenesis, by exploiting new insights from Network Medicine and drug repurposing strategies. To identify new drug-ALS disease associations, we exploited SAveRUNNER, a recently developed network-based algorithm for drug repurposing, which quantifies the proximity of disease-associated genes to drug targets in the human interactome. We prioritized 403 SAveRUNNER-predicted drugs according to decreasing values of network similarity with ALS. Among catecholamine, dopamine, serotonin, histamine, and GABA receptor modulators, as well as angiotensin-converting enzymes, cyclooxygenase isozymes, and serotonin transporter inhibitors, we found some interesting no customary ALS drugs, including amoxapine, clomipramine, mianserin, and modafinil. Furthermore, we strengthened the SAveRUNNER predictions by a gene set enrichment analysis that confirmed modafinil as a drug with the highest score among the 121 identified drugs with a score > 0. Our results contribute to gathering further proofs of innovative solutions for therapy in ALS pathogenesis.

show abstract

Section: Discussionmentioning

confidence: 99%

Drug Repurposing: A Network-based Approach to Amyotrophic Lateral Sclerosis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Commonly used stimulants include amphetamines, caffeine, cocaine, methylphenidate, and modafinil. As a drug class, stimulants are considered to have high potential for misuse due to their euphoric properties [104]. In fact, there were 1.1 million users of recreational stimulants among persons 12 years or older in the United States as of 2010 [105].…”

Section: Stimulantsmentioning

confidence: 99%

Anesthetic Concerns in Psychiatric Disease

Martinez-Baladejo¹,

Liongson²,

Wong³

et al. 2023

Updates in Anesthesia - The Operating Room and Beyond

View full text Add to dashboard Cite

As the prevalence of mental health illnesses rises worldwide, the use of psychotropic medications follows. Undoubtedly, many patients using psychotropic medications will undergo procedures requiring anesthesia both in the operating room and outside of it. This chapter focuses on psychotropic medications that may complicate the surgical and postoperative course of patients undergoing anesthesia. Toward this aim, we performed a literature review using targeted key terms. Relevant articles were cited, and findings are summarized in this narrative review. We begin with discussing psychotropic medication pharmacology, drug-drug interactions, and side effects, emphasizing their interaction with anesthetic agents. We summarize the current recommendations for managing these medications in the perioperative period. In the discussion section, we focus on highlighting future directions for the intersection between psychotropic medications and anesthesia. Overall, we provide insight into the perioperative management of patients taking psychotropic medications, the point of intersection between the fields of psychiatry and anesthesia.

show abstract

“…narcolepsy, obstructive sleep apnea, shift work sleep disorder, and idiopathic hypersomnia). 3 In Europe, MODA is currently only indicated for the treatment of narcolepsy at a daily dose of 200 mg (up to 400 mg). The lowest effective starting dose is recommended to minimize the risk of drug-related adverse effects.…”

Section: Pharmacology Of Modafinilmentioning

confidence: 99%

“… 10 The precise mechanisms of action are unknown, but they have been shown to increase dopaminergic neurotransmission by blocking dopamine transporters. 3 Potential side-effects include alterations of mood, perception, thinking, and feeling. 3 However, increases in dopamine levels are milder and longer-lasting than other psychostimulants, making them well-tolerated with attenuated withdrawal symptoms and low addictive potential.…”

Section: Introductionmentioning

confidence: 99%

“… 3 Potential side-effects include alterations of mood, perception, thinking, and feeling. 3 However, increases in dopamine levels are milder and longer-lasting than other psychostimulants, making them well-tolerated with attenuated withdrawal symptoms and low addictive potential. 10 Despite having the same half-life (∼13 h), MODA and the R-isomer armodafinil differ in their elimination profiles.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Improvement of lupus-associated fatigue with modafinil: Report of two cases

Korsten

Piantoni

2021

Lupus

View full text Add to dashboard Cite

Fatigue is a frequently reported and disabling symptom in patients with systemic lupus erythematosus (SLE). The management of Lupus-associated fatigue (LAF) is complex and requires the exclusion of disease activity and comorbidities as potentially treatable causes. Standard of care recommendations includes psychological counselling and regular physical activity. However, many SLE patients still report the persistence of LAF despite these measures. Therefore, pharmacological management may be required, which has been insufficiently investigated in clinical trials. Here, we report two patients who improved with pharmacological treatment with modafinil (MODA), a central nervous system stimulant. Both patients had an overall low disease activity (SLEDAI-2K score of 0). Their FACIT fatigue scores were 15 and 20, respectively (with a maximum score of 52, where 52 indicates the best quality of life). With MODA treatment, the first patient’s FACIT fatigue score improved from 15 to 42, the second patient’s score from 20 to 37. In the latter patient, it returned to 21 after stopping the drug and increased back again to 37 after re-treatment. In conclusion, our report demonstrates, for the first time, that MODA treatment is a potential pharmacological treatment option in selected patients with LAF. Clinical trials in SLE are required to confirm our observations.

show abstract

A review on modafinil: the characteristics, function, and use in critical care

Cited by 25 publications

References 24 publications

Drug Repurposing: A Network-based Approach to Amyotrophic Lateral Sclerosis

Drug Repurposing: A Network-based Approach to Amyotrophic Lateral Sclerosis

Anesthetic Concerns in Psychiatric Disease

Improvement of lupus-associated fatigue with modafinil: Report of two cases

Contact Info

Product

Resources

About